# OnCo record paper-codebreak-200-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-codebreak-200-lancet-2023" ;
  schema:name "CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug"@en ;
  schema:description "The first drug to directly block mutant KRAS beat docetaxel chemotherapy on delaying progression in KRAS G12C lung cancer, but only by about a month, and did not improve survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=CodeBreaK+200+sotorasib+docetaxel+de+Langen+Lancet>, <https://clinicaltrials.gov/study/NCT04303780>, <https://doi.org/10.1016/S0140-6736(23)00221-0>, <https://pubmed.ncbi.nlm.nih.gov/36764316/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)00221-0> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "de Langen AJ, Johnson ML, Mazieres J, et al." ;
  onco:related <https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/>, <https://onco.cc/key-papers/paper-kras-nsclc-n-engl-j-med-2021/>, <https://onco.cc/roadmaps/kras-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:institutions <https://onco.cc/institutions/nki/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/driver-mutation/> ;
  onco:trials <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/codebreak-100/> ;
  onco:people <https://onco.cc/people/luis-paz-ares/>, <https://onco.cc/people/solange-peters/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-combination-space/> ;
  onco:journals <https://onco.cc/journals/lancet/> .